Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Solana Company(HSDT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for HSDT
11/03/2026: HSDT (1-star) is currently NOT-A-BUY. Pass it for now.
Helius Medical Technologies is a specialized medical device company known for its PoNS neurostimulation therapy, which aims to improve gait and balance in patients with neurological disorders. The company's primary strength lies in its proprietary non-invasive technology and successful regulatory milestones. Its main growth opportunity involves expanding insurance coverage and targeting new clinical conditions to drive commercial adoption. However, it faces significant risks including financial losses, intense competition from well-established medical device players, and the challenge of scaling a niche therapy. Helius is best suited for high-risk investors interested in emerging health technology, and stakeholders should monitor ongoing clinical evidence generation and reimbursement progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | The company is at a very early commercial stage with high execution risks. |
| Momentum investor | Weak fit | Current trends do not support a consistent momentum signal. |
| Value investor | Weak fit | The company lacks positive earnings and sustainable cash flow for traditional value metrics. |
| Dividend investor | Weak fit | No dividend payments or capacity for payouts. |
| Low-risk investor | Weak fit | High volatility and operational risk make this unsuitable for low-risk profiles. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to significant price swings due to its low float and early-stage status. |
| Valuation risk | High | Valuations are highly speculative based on future clinical and commercial success. |
| Competition risk (Medical Devices) | Medium / high | The company faces well-capitalized competitors in the broader neuro-rehab space. |
| Business quality | Low | The business model is in the early stages of proving commercial viability. |
| Dividend income | Low / none | The company is focused on growth and survival, not capital return. |
| Execution risk | High | Achieving widespread clinical adoption and reimbursement is a significant barrier. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -37.35% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/03/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 131.19M USD | Price to earnings Ratio 0.04 | 1Y Target Price 3.5 |
Price to earnings Ratio 0.04 | 1Y Target Price 3.5 | ||
Volume (30-day avg) 499.8K shares | Beta 1.05 | 52 Weeks Range 1.19 - 5.77 | Updated Date 11/03/2026 |
52 Weeks Range 1.19 - 5.77 | Updated Date 11/03/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 53.74 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| PoNS Device Sales | Revenue from the sale of the Portable Neuromodulation Stimulator devices to clinics and patients. | The company makes money primarily by selling its specific medical device for neuro-rehabilitation. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 0.04 | Forward PE - | Enterprise Value 130.44M | Price to Sales(TTM) 10.87 |
Enterprise Value 130.44M | Price to Sales(TTM) 10.87 | ||
Enterprise Value to Revenue 11.18 | Enterprise Value to EBITDA -0.01 | Shares Outstanding 65.10M | Shares Floating 45.07M |
Shares Outstanding 65.10M | Shares Floating 45.07M | ||
Percent Insiders 16.2 | Percent Institutions 25.37 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.